The goal of this observational study is to test the effectiveness of quantitative early biomarkers in the sleep electroencephalogram (EEG), namely sleep spindles, as predictors of early sensorimotor maturation and long-term motor outcome. Spindles are discrete events, prominent over sensorimotor areas, that reflect motor learning overnight consolidation. They represent a potential marker for the investigation of altered early sensorimotor reorganization and long-term motor outcomes in the case of neuromotor pathologies. To test this hypothesis, we will validate the prognostic accuracy of a semi-automated EEG sleep-spindles analysis in two clinical populations: 1) infants with a perinatal brain lesion, at risk of Cerebral Palsy (CP), 2) infants with Spinal muscular atrophy type 1 (SMA1), a neuromuscular disease detectable at birth with variable response to early pharmacological treatment. A group of typically developing infants (at very low neurological risk) will be enrolled in the study as control group. All participants will undergo two sleep EEG recordings at 2-5 months (T1) and 12 months (T2), respectively. Short-term neuromotor outcome will be evaluated at T1 and T2, through standard and validated assessment. Long-term neuromotor development will be defined at 18 months (T3; i.e. CP vs NO CP; SMA treatment responders vs No responders). Primary clinical and motor outcomes will be used for estimating the effectiveness of spindles' features at T1 and T2 as predictors of later clinical and motor outcomes at T3. EEG sleep features will be considered both cross-sectionally, at each time point (T1, and T2), and from a longitudinal perspective. Differences in the EEG sleep-spindle features will be evaluated within- and between-groups.
Study Type
OBSERVATIONAL
Enrollment
80
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Milan, MI, Italy
IRCCS Fondazione Stella Maris
Calambrone, PI, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Clinical dichotomous outcome
For infants with perinatal brain damage, the primary outcome will be the diagnosis of CP: CP-YES vs CP-NO. For infants with SMA, the primary outcome will be the response to treatment: responders (SMA-R) vs non-responders (SMA-NR).
Time frame: 18 (+/- 3) months
Sleep EEG (T1,T2) - quantitative sleep spindles analysis
Primary predictive measure of the study
Time frame: 2-5 months, 12 (+/- 1) months
General Movements Assessment (GMA; T1)
Short-term motor outcome
Time frame: 2-5 months
Peabody Developmental Motor Scale (PDMS-II; T2 and T3)
Long-term motor outcome
Time frame: 12 (+/- 1) months, 18 (+/- 3) months
Hammersmith Infant Neurological Examination (HINE; T1, T2 and T3)
Clinical short- and long-term outcome
Time frame: 2-5 months, 12 (+/- 1) months, 18 (+/- 3) months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.